Perry D. Nisen
About Perry D. Nisen
Independent director at Teva since 2017; age 69. Trained physician-scientist with deep R&D leadership (ex-GSK SVP Science & Innovation; ex-Abbott oncology R&D leader) and current operating biotech CEO (Quanta Therapeutics). Education: BS Stanford; MS (molecular biology); MD/PhD Albert Einstein College of Medicine. Classified as independent under NYSE rules; standing for re-election through Teva’s 2028 AGM term .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Sanford Burnham Prebys Medical Discovery Institute | Chief Executive Officer & Donald Bren Chief Executive Chair | 2014–2017 | Led translational research institute; informs Teva’s Science & Technology oversight |
| GlaxoSmithKline | Senior Vice President, Science & Innovation | 2004–2014 | Global R&D leadership; relevant to pipeline governance |
| Abbott Laboratories | Divisional VP, Global Oncology Development; Divisional VP, Cancer Research | 1997–2004 | Oncology development execution; IP and clinical risk assessment experience |
| UT Southwestern Medical Center | Lowe Foundation Professor of Neuro-Oncology | Prior to 1997 | Academic medicine and research credentials |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Quanta Therapeutics, Inc. (private) | Chief Executive Officer | July 2021–present | Operating biotech CEO; potential information flow from industry networks |
| Sofinnova Investments | Executive Partner (Private Equity), then Consultant | 2018–Jan 2021 (consultant thereafter) | Investor/consultant experience supports finance/BD oversight |
Board Governance
- Committee assignments: Chair, Science & Technology; Member, Compliance; Member, Human Resources & Compensation .
- 2024 attendance: Board met 7 times; committees met 4–5 times; Nisen attended 100% of Board and committee meetings .
- Independence: 11 of 12 directors independent; nominees (including Nisen) qualify as independent .
- Executive sessions: Held generally at each Board meeting, chaired by independent Chair (Dr. Barer) .
- Risk oversight: Science & Technology Committee covers R&D/IP risk; Compliance Committee covers legal/regulatory/sustainability; HR & Compensation oversees pay/succession .
Fixed Compensation
| Component (2024) | Amount (USD) | Basis |
|---|---|---|
| Board annual retainer | $130,000 | Non-employee director cash fee |
| Science & Technology Committee (Chair) | $20,000 | “Other standing committee” chair fee |
| Compliance Committee (Member) | $10,000 | “Other standing committee” member fee |
| HR & Compensation Committee (Member) | $15,000 | HR & Compensation member fee |
| Total cash fees (reported) | $175,000 | Matches itemized components above |
Proposal 5 (approved June 5, 2025) shifts director cash retainer to $100,000 (from $130,000) effective 2025, increasing equity mix (see Performance Compensation) .
Performance Compensation
| Equity Award Type | Grant Date | RSUs (#) | Grant-Date Fair Value per Share | Vesting Terms |
|---|---|---|---|---|
| Annual RSUs | June 2024 | 9,632 | $16.61 | One-year cliff; immediate vesting upon end of service except removal for breach |
- 2024 stock awards reported value: $159,988; total 2024 director compensation for Nisen: $334,988 .
- From 2025, annual RSU grant value increases to $250,000; vesting remains at 1-year cliff (approved in Proposal 5) .
- Performance metrics tied to director equity: None disclosed (director RSUs are time-based only) .
Other Directorships & Interlocks
| Company | Role | Tenure | Notes |
|---|---|---|---|
| Mirna Therapeutics, Inc. | Director (public company) | 2016–2017 | Past public board service |
Committee interlocks: HR & Compensation Committee disclosed no interlocks or insider participation in 2024; members were independent (Nisen included) .
Expertise & Qualifications
- Scientific/R&D leadership across big pharma and biotech; supports oversight of pipeline, clinical risk, and IP strategy .
- Academic neuro-oncology background; enhances diligence on CNS portfolio (e.g., AUSTEDO, olanzapine LAI) .
- Operating CEO and PE consulting experience; contributes to investment, BD, and governance rigor .
Equity Ownership
| Holder | Ordinary Shares Beneficially Owned (Apr 1, 2025) | % of Shares Outstanding | Unvested RSUs (Dec 31, 2024) |
|---|---|---|---|
| Perry D. Nisen | 95,683 | <0.01% (approx. 0.0083% of 1,146,959,855 shares) | 9,632 |
- Director stock ownership guidelines: 5x annual cash retainer historically; increased to 7x retainer subject to Proposal 5 approval .
- Hedging/pledging: Company prohibits hedging and pledging by executive officers and non-employee directors, reinforcing alignment .
Say-on-Pay & Director Election Results (2025)
| Item | For | Against | Abstain | Broker Non-Vote |
|---|---|---|---|---|
| Director Election – Perry D. Nisen | 644,697,802 | 145,078,739 | 13,039,105 | 61,943,377 |
| Say-on-Pay (NEOs) | 688,836,027 | 99,207,637 | 14,771,995 | 61,943,377 |
| Proposal 5A – Update Non-Employee Director Compensation | 773,824,912 | 27,111,172 | 1,878,351 | 61,943,377 |
| Proposal 5B – Update Non-Executive Chair Compensation | 772,020,910 | 29,129,637 | 1,665,087 | 61,943,377 |
- Nisen support equated to ~80.3% of votes cast (For/(For+Against+Abstain)), signaling solid investor confidence .
- High approval for director compensation changes reflects acceptance of increased equity emphasis and ownership alignment .
Governance Assessment
-
Strengths:
- 100% attendance and multi-committee engagement (Chair, Science & Technology), indicating high commitment and effective oversight .
- Independent status and robust committee coverage (R&D, Compliance, HR/Comp) directly aligned with Teva’s strategic and risk areas .
- Equity-heavy director pay structure (post-2025) and stricter ownership guidelines improve alignment with shareholders .
-
Potential conflicts/monitoring points:
- Concurrent CEO role at Quanta Therapeutics (private) creates theoretical interlock risk if transactions arise; Teva’s Audit Committee oversees related-party approvals; no Nisen-related transactions disclosed .
- Hedging/pledging prohibition mitigates alignment concerns; monitor ongoing compliance and ownership guideline attainment (not disclosed by individual) .
-
Signals to investors:
- Strong shareholder support for Nisen’s re-election and for director compensation recalibration to equity reinforces confidence in governance and board effectiveness .
- Science & Technology committee leadership positions Nisen to influence pipeline prioritization and R&D risk management in line with Teva’s “Pivot to Growth” strategy .